No price history available.
Key financial summary
Financials in JPY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | ¥m | 70,131 | 55,146 | 58,195 | 61,555 | 64,486 | 64,149 | N/A | N/A |
| Operating profit | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | ¥m | 678 | 696 | 218 | 580 | 616 | 648 | N/A | N/A |
| EPS reported | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in JPY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Yamashita Health Care Holdings,Inc. engages in the supply of medical equipment in Japan. The company offers diagnostic imaging devices, such as MRI and CT, endoscopic systems, operating tables, and surgical equipment comprising electric scalpels, orthopedic implants, various catheters, and disposable medical materials; plans, outsources, manufactures, consigns, imports, and sells implants that are embedded in the body in the field of orthopedics; and sells and maintains medical equipment, which include dialysis machines/dialysis consumables, peritoneal dialysis, lithotripsy, and stents. It also provides consulting services related to the construction of nursing care facilities, M&A, and support to medical and nursing care institutions; and develops reservation solutions for hospitals consisting of search portal sites for hospitals and clinics, online reservations, posting agency for customer satisfaction surveys, and network security systems sales. In addition, the company offers network integration and software design and development; equipment used in physical therapy and rehabilitation, as well as related consumables such as surgical gowns, gloves, and bandages; manufactures and sells medical devices, and conduct contract research on medical ultrasound, as well as the development, sales, and consulting of medical devices and peripheral devices that use ultrasound. Yamashita Health Care Holdings,Inc. was founded in 1926 and is based in Fukuoka City, Japan.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Yamashita Health Care Holdings,Inc. (9265.T)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Yamashita Health Care Holdings,Inc. engages in the supply of medical equipment in Japan. The company offers diagnostic imaging devices, such as MRI and CT, endoscopic systems, operating tables, and surgical equipment comprising electric scalpels, orthopedic implants, various catheters, and disposable medical materials; plans, outsources, manufactures, consigns, imports, and sells implants that are embedded in the body in the field of orthopedics; and sells and maintains medical equipment, which include dialysis machines/dialysis consumables, peritoneal dialysis, lithotripsy, and stents. It also provides consulting services related to the construction of nursing care facilities, M&A, and support to medical and nursing care institutions; and develops reservation solutions for hospitals consisting of search portal sites for hospitals and clinics, online reservations, posting agency for customer satisfaction surveys, and network security systems sales. In addition, the company offers network integration and software design and development; equipment used in physical therapy and rehabilitation, as well as related consumables such as surgical gowns, gloves, and bandages; manufactures and sells medical devices, and conduct contract research on medical ultrasound, as well as the development, sales, and consulting of medical devices and peripheral devices that use ultrasound. Yamashita Health Care Holdings,Inc. was founded in 1926 and is based in Fukuoka City, Japan.